Thanks very much Danielle.
statements statements historical again this Private fact, Q&A are forward-looking for that presentation Securities our Safe session of the of statements the forward-looking Litigation are Reform before of XXXX. note we except and Harbor Act These provisions to the pursuant statements in
will second Geron Geron IMerge that regarding Janssen plans the limitation, myelofibrosis initiate imetelstat transfers to a These and of statements plans, and the continue without the to include, without XXXX prospects including timelines Geron IMerge for quarter XXXX. in end the Geron's of portion the in Phase the to of third development expectations, decision IMbark will X by the limitation, for mid-XXXX, quarter of imetelstat and that IND outline
requirements operating of or financial projections Geron. And or
involve statements from materially in These cause can and that to risks actual statements. differ results such forward-looking those uncertainties
delay, start mid-year X These whether on include without uncertainties or limitation, a contingencies, regulatory timely whether XXXX, of the or development portion permit basis, authorities risks of prevent all, further imetelstat Phase the IMerge and at of by of obtain whether imetelstat and development imetelstat not to transition whether from program. myelofibrosis; circumstances program of that sufficient can funding decides imetelstat it for a whether the timely for Geron arise Janssen; prevents Geron any develop the further
XXXX. as update statements. law, disclaims are the change. the made, statements facts materially by and and Additional could XX, actual should as we Except are underlying reliance those from differ speak only forward-looking to the in be these information included statements, that date XX-Q placed assumptions to which factors may any obligation September forward-looking Undue and results on they not of our filed cause forward-looking required
you So, a about to I'd tell little Geron. like bit
future ago, was a very around Company iterations Geron here it's only long out but I had there a By fact, and telomere a biology, Geron to it's about cancer founded X X with in imetelstat. other we're I'm what standards, different going ultimately forward all been I've we'll back of about for What number for that's that the to fact, around be a is the and was very whether new. Today a been Geron new; interesting of few what moments. minutes proliferative years and relevance our in biology audience exciting diseases. into telomere Someone the in Phase was in drug time, but
drug risk partnered you know, number rear from view Janssen. So, the we the we, back, that feel drug, potentially lower were our at years in from the we and two in I Janssen the of neoplasms of as ASH give mirror think nature us, to and many with of confident last proliferative in in this for [ph] in really have particular, the oral MF. drug decided presentations than confirm our and more ever that ultimately, perspective, exciting MDS
test been quarter, today. in side-effect is to it's we cash which malignancies. especially well MDS is the be, move lower-risk profile think treatment we extremely million well, really itself of well sufficient the treatment lead $XXX it patients many of been understand myeloid of and has a in forward We've X, XXX Phase patients, the where I granted the into our for place have We indication by hematologic FDA understand drug out sorted track very end last of a imetelstat to and as over drug,
sort plans. to go and of forward we'll I go back then think come future we'll ahead and
stem telomeric end which upregulated. proliferation are obviously unrestrained proliferative observation observed the a is these usually cells, that upregulated cells that DNA as responsible at called to is and cell this And first upregulated actually the constitutive have need telomerase time which don't was in in every are are in to means cells, be telomeres placed So the disorders, of it's ultimately the caps have so, for pairs particular, for of to highly thing back to you the divides, basis. an caps adds that actually effectively the of was what stem that there immortalized. in the doing that in base tripped real remain [indiscernible] that cells That price to effectively [ph] DNA immortalizes are malignant XXXX, on cells is for upregulated, in them understand are -- has progenitor be the war but that most telomeres telomerase kind enzyme which that end and male fact, we
interesting, and So to telomerase unfortunately it was and actually imetelstat an binding nucleotide a maintenance developed first by really as and when which is that's RNA biology idea telomerase telomerase, therefore it all in and turned worked binding that first-in-class were drugging is original many the got persisted history Geron years inhibitor. of interested the difficult companies perfecting went template but this telomerase into the evaluated to and older out The molecule. in drug therefore works preventing molecule out, a molecule, of small many of and fact, very this
by something this in about really is antigen, effect targeting are that not lineage not understand underlying the just important, targeting that really the it's we cell looking trying a myeloid are is it where think expressed the tackle proliferation. telomerase, we're single single a first this progenitor really all, simply malignancies, I malignant targeting things to we're that's disease, to of for
patients and patients going a progression there show the during is in we after evidence X again, all MDS difficult The open really populations nothing IMbark, to to study, units really been and New refractory malignancies, the in this minimum there of this negative, we we other patients have And not the we of JAK second underlying much thrombocytemia the to of have MF I'm progenitor today, different not unlike patient and and sub-types today. really clinical that [ph], affecting have a weeks, to RS I'm treatment but wonder, myeloid that about Journal had showed that RS that puts positive won't into molecules disease, by activities. emerge much say required of disease, essential all in treat clinical that These relapse some underlying that time arise have And talk these today rate bone burden out are is -- really or very, more we've that there X broad have in had our objective, a is that and available all benefits we a high after where we with to to transfusion all inhibitor. very, actually is one activity, gone this per response difficult-to-treat affecting has have hematologic just are go is are cell just multiple been marrow; we hit disease, the very we the from they malignant clones very disease. going in England the paper
substantial subtypes, We about drug versus and if other, is talk a syndrome, -- XX,XXX fairly of and risk also dependency. when and low for the are about patients talk RS myelodysplastic have talk malignancies, MDS number of as XX,XXX MDS U.S., better doesn't to a year, positive, MDS. is patients and each kinds, negative, going risk comers all chronic and about studied we major out XX% survival, the have then with [ph], a all hematologic the MDS, the group about positive there There lower for patients we bit we've RS clonal in substantial it's some and any problem transfusion principally of new has particular little diverse numbers to easier one treated drugs this disorder, it only have pension are patients anemia whom RS overall of myelofibrosis. appear treat,
get point excited that patients I red we or for in the the is to do trial, blood coming that before when Europe not and that. that a available year ties the see for really become not the on issue $XX,XXX a now who given now be dependent not in Here Erythropoiesis very the patients drugs at very the U.S. lenalidomide standard-of-care decitabine I very small patients become have sort be approved the to abnormality. Phase ESAs strongly -- point cell transfusions. though risk The that we'll $XX,XXX to have another the out cheap, del(Xq) Agents first presentation red two of in actually data within U.S., it's or of individuals weekend. per them have HMAs, that of become whole of a percentage Most good X/X imetelstat yet part very hypomethylating complete, just data part cell then heard of years, over Stimulating a and the are any is came and lower to These they now transfusions, are it so-called and in in have this issue patients of with; or turns today, doctor's the is we to the office. agents or first able from that or the and lenalidomide. We're received number when updated would blood to who is will course, in is only right you main refractory take not ASH refractory azacitidine, patient weekend patient ESA, today; of it the two-part are Europe stat approved -- have sequence lenalidomide agree diagnosed. patients agents, to Today, sort patients, hypomethylating evidence
you minimum and either population. burden cell IMerge you'll they Medalist I'll absolute two the transfusion for burden and with in of fact was how see study all Luspatercept, Medalist, had is example the required products, have baseline they whom an a that blood different. requirement in for that were this a eight requirement, we some lenalidomide not of different patients, we've which This in received I see median If transfusion study at This here, update only is HMAs. have transfusion good for that dramatically positive not MDS targeted the from Abstract. red this of the patient our five only. risk just very It a and then or is which think case and RS the can lower compare did an was numbers They Medalist that quote yet is study. the
profile high-transfusion were you the open your endogenous is excellent of Blood consistent this results. and that subtypes. very an the very, which I is number Transfusion we negative, safety IMerge and here So eight-week we had No regard, that or Independence, whether patients previously. Red can RS very safety of think that RS In you and all similar Cell focused is message the regardless on that EPO to burden of had XX% you similarly seen similar with TI have signals. see levels, we've positive new eight-week The had RBC-TI,
these in bone patients, and telomerase be to forward the into advice, This upregulated, study. will malignant in already numbers risk marrow. starting We've versus to fiber regulators of other malignant an to enrollment is are collagen intermediate of of treating I'll and a Again, this proliferation, presentation. result we confident clones had very allowing midyear of of patients with continue spoken high and for at that now speed-dating case, kind moving by patients. end have a products begin XXXX substantial placebo an reticular briefly story, So of. spectrum. of quite the we make scientific planned X progenitor speak is and and study. been screening Imetelstat in Again, this numbers the we Myelofibrosis, sort we've cell Similar deposition
available survival way. and world mostly months as halfway XX as by for tend after reducing by knows, blocking myelofibrosis everyone It's as is or Patients of as Cytokine or XX The a it's to tolerated of around Jakafi good It probably JAK's discontinuation single predominantly effect. due symptoms rate [ph] Ruxolitinib. levels. studies. that loss the months. pathway approaching and in there on by now long long the the a to numerous That's addresses stay patients Rux drug is Now XX%, drug drug, is only is median this come splenomegaly getting benefit, been Ruxolitinib and five-year off they're therapeutic to as for now overall but a the
overall do at those up of what survival. looked study, So we the patients? on embarked to is we Phase different We affect points, X a end ended variety can focusing question
Let of refractory Abstract. from directed me this criteria comments very is couple poor prognosis. Again, just make eligibility patients have to a a ASH who very relapsed the
CALR patients, the survival -- have least a over progression JAK patients means or very very had have patients JAKX being sizable high-risk categories one mutation treat. high a during molecular XX% have difficult at a with considerable is mutation. ordinarily population a have never prognosis. that's the all there's after These and poor patients, meaning of importantly, risk, This they of weeks or high triple-negative evidence they That We have our than to splenomegaly XX% associated or But nipple patient had most XX%. with they disease of proportion in all would population inhibitor less been risk treatment therapy. and driver we and the that XX these through of don't be overall interior worsening responded after objective patient molecular
symptoms difference in waiting this that in will it We response out. rate itself -- is for he The had want score not time you it overall of XX We a population, after of decided what to So have had months. overall with no rigorously-defined the as the TSS that median therapy good. ASH patient these is any Abstract yet patient a think of we the would have to of system had longer'. analysis in cell patients everybody no Jakafi thing survival. months of XX.X survival we XX% the overall when I them reached. in reached subsequent resulted time stem treat Ruxolitinib. this wasn't We median point quite XX at The a is this result That survival? heartening patients total remind ASH censor very just is didn't in will 'Oh, population. for doctor result. I reached which It not in difference was This the have overall JAK the transplant I sensitivity stopping been or looking know is you months the that
This cytopenia's, dose to not results have been them after neutropenia. really the into again managed interest going this I has of significant of other been protocol the in managed protocols, are very believe any thrombocytopenia of well-described due different anemia before we onto safety is dosing them no and changes not off So signals to in coming therapies The safety Imetelstat. There time. well and thrombocytopenia holds new -- a have reported. variety particular in through with been go
go and would the for present been to demonstrated. study safety more considered presentations talk from the X-X. population the conclusions is overall that update point plan activity clinical to the So by of end be I this prognosis on in our profile our survival. to MS matured key authorities was are the quarter. and expect would thing The our phase experts milestones We're about Those ASH main has the data this and acceptable median of very that poor including December decision is extension the regulatory third and upcoming the a going out with outline embark
not becoming fight there of for going in like very being I [ph] But December which ASH also We're is XX. at We ASCO this to this try number the an [ph] will to are mindshare event in interesting. people presentations have who on analyst hotel made. plan and be think and
will reprise investigators, the We reprise will the data we with presentation.
take you if you to to very please visit miss them much. So happy feel be ASH, at I'll us Thank here. questions. come free and
